Cantargia AB (CANTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cantargia AB (CANTA) has a cash flow conversion efficiency ratio of 0.943x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr280.72 Million ≈ $30.21 Million USD) by net assets (Skr297.57 Million ≈ $32.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cantargia AB market capitalisation for the company's overall valuation and market capitalisation.
Cantargia AB - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Cantargia AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cantargia AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cantargia AB ranked by their cash flow conversion efficiency. Explore cash flow quality index of Cantargia AB to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Universal Textile Co Ltd
TW:1445
|
0.037x |
|
NK Co. Ltd
KO:085310
|
0.015x |
|
DT Cloud Star Acquisition Corporation Ordinary Shares
NASDAQ:DTSQ
|
-0.001x |
|
UNITEKNO Co.Ltd
KQ:241690
|
-0.002x |
|
Astra Exploration Inc
V:ASTR
|
-0.746x |
|
YATRA ONLINE DL-0001
F:26Y
|
-0.006x |
|
OCR Group Bhd
KLSE:7071
|
-0.107x |
|
IGLOO SECURITY Inc
KQ:067920
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Cantargia AB (2011–2024)
The table below shows the annual cash flow conversion efficiency of Cantargia AB from 2011 to 2024. View CANTA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr116.30 Million ≈ $12.52 Million |
Skr-162.75 Million ≈ $-17.51 Million |
-1.399x | +17.63% |
| 2023-12-31 | Skr168.74 Million ≈ $18.16 Million |
Skr-286.66 Million ≈ $-30.85 Million |
-1.699x | -84.45% |
| 2022-12-31 | Skr389.68 Million ≈ $41.94 Million |
Skr-358.92 Million ≈ $-38.62 Million |
-0.921x | -41.63% |
| 2021-12-31 | Skr532.75 Million ≈ $57.33 Million |
Skr-346.44 Million ≈ $-37.28 Million |
-0.650x | -270.89% |
| 2020-12-31 | Skr891.93 Million ≈ $95.99 Million |
Skr-156.39 Million ≈ $-16.83 Million |
-0.175x | +77.58% |
| 2019-12-31 | Skr142.27 Million ≈ $15.31 Million |
Skr-111.25 Million ≈ $-11.97 Million |
-0.782x | -15.81% |
| 2018-12-31 | Skr155.04 Million ≈ $16.69 Million |
Skr-104.69 Million ≈ $-11.27 Million |
-0.675x | -304.30% |
| 2017-12-31 | Skr246.12 Million ≈ $26.49 Million |
Skr-41.10 Million ≈ $-4.42 Million |
-0.167x | +84.31% |
| 2016-12-31 | Skr37.13 Million ≈ $4.00 Million |
Skr-39.53 Million ≈ $-4.25 Million |
-1.065x | +1.35% |
| 2015-12-31 | Skr28.05 Million ≈ $3.02 Million |
Skr-30.28 Million ≈ $-3.26 Million |
-1.079x | -164.11% |
| 2014-12-31 | Skr4.10 Million ≈ $440.95K |
Skr6.90 Million ≈ $742.32K |
1.683x | +163.81% |
| 2013-12-31 | Skr3.13 Million ≈ $337.02K |
Skr-8.26 Million ≈ $-889.18K |
-2.638x | -114.81% |
| 2012-12-31 | Skr3.08 Million ≈ $331.15K |
Skr-3.78 Million ≈ $-406.73K |
-1.228x | +35.02% |
| 2011-12-31 | Skr1.54 Million ≈ $165.99K |
Skr-2.92 Million ≈ $-313.74K |
-1.890x | -- |
About Cantargia AB
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more